Richard Eastell

From Wikipedia, the free encyclopedia

Richard Eastell MD, FRCP (London, Edinburgh, Ireland), FRCPath, FMedSci is a British medical doctor and Professor of Bone Metabolism at the University of Sheffield.[1] He was born in Shipley (West Yorkshire) and attended the Salt Grammar School,[citation needed] later graduating from the University of Edinburgh in 1977 with an MB ChB and in 1984 with an MD[2] and achieved prominence as an expert in osteoporosis.

Bone Metabolism[]

Professor Eastell has pioneered new techniques for measuring calcium uptake and vitamin D conversion and is a leading expert in osteoporosis diagnosis, implementation of bone turnover markers and new osteoporosis treatments.

While at the Mayo Clinic, Eastell developed new non-radioactive methods for measuring how calcium was absorbed from the diet and a new technique for measuring 1,25-OH2D3 production as well as refining the use of bone densitometry and a new approach for identifying vertebral fractures on radiographs of the spine. After returning to the UK, Eastell set up a metabolic bone service at the Northern General Hospital. More recent contributions have been within the area of bioclinical bone turnover markers and leadership of clinical trials in the osteoporosis area for new osteoporosis treatments.

Eastell has supervised the study for 37 doctoral degrees over the past 30 years and published over 550 research papers.

Controversies[]

Eastell was the subject of a 2005 report in the Times Higher Education Supplement concerning allegations that he had incorrectly claimed to have had full access to data for a trial of the Procter & Gamble drug Actonel. The report claimed that the analysis for the trial had been carried out by Procter & Gamble and that Eastell did not in fact have complete access to the data. Eastell wrote a letter in 2007 to the editors of the Journal of Bone and Mineral Research, where the paper in question was published in 2003,[3] accepting that he had not disclosed limitations on data access as required by the journal and acknowledging certain errors in the paper.[4] At a General Medical Council "fitness to practice" hearing in November 2009, it was determined that Eastell's actions had not been "deliberately misleading or dishonest", although he may have been negligent in making "untrue" and "misleading" declarations; the council did not make a finding of misconduct.[5]

The THE's report on Eastell was in part the result of whistleblowing by another Sheffield academic, Aubrey Blumsohn, who was initially suspended by the university and subsequently left the university with a "six-figure" payout.[6][7] Other bone medicine academics, speaking on BBC Radio 4's programme "You and Yours", took the view that the paper in question had overstated the effectiveness of the drug.[8]

Eastell resigned as director of research at Sheffield National Health Service Trust in 2006 after allegations of "financial irregularities" related to charging the NHS for laboratory tests in connection with his university research. His resignation followed suspension by the NHS when the allegations were made in May 2005.[9][10] The NHS trust did not produce an investigation report, stating that this was pre-empted by Eastell's resignation.

In 2010 Eastell was involved in a further dispute with a colleague over a clinical trial and the right of that colleague to present commercially sensitive data.[11]

Eastell is Professor of Bone Metabolism at the University of Sheffield and Director of the Mellanby Centre for Musculoskeletal Research.[12]

Awards and honours[]

  • Corrigan Lecturer, Royal College of Physicians of Ireland, 1998[13]
  • Kohn Award, National Osteoporosis Society, 2004[14]
  • Society for Endocrinology Medal, 2004[14]
  • Winner of the ECTS/ASBMR Golden Femur Award 2010 and 2012.
  • Frederick C Bartter Award from the American Society for Bone and Mineral Research, 2014.[15]

See also[]

References[]

  1. ^ Academic Unit of Bone Metabolism
  2. ^ Eastell, Richard (1984). Investigation of metabolic bone disease by in vivo neutron activation analysis (Thesis). hdl:1842/18160.
  3. ^ Eastell et al. (2003), "Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate", Journal of Bone and Mineral Research, 18:1051–1056
  4. ^ Phil Baty, "Bone professor faces GMC probe", Times Higher Education, 22 September 2009
  5. ^ Phil Baty, "Academic made ‘untrue’ declaration about ‘full access’ to research material, GMC finds", Times Higher Education, 10 November 2009
  6. ^ Phil Baty, "Payout in P&G drug data row", Times Higher Education, 7 April 2006
  7. ^ Jennifer Washburn, "Rent-a-Researcher: Did a British university sell out to Procter & Gamble?", Slate, 22 December 2005
  8. ^ "Experts cast doubt over scientists' claims for Actonel", Times Higher Education, 24 February 2006
  9. ^ Phil Baty, "Drugs trial row scientist resigns", Times Higher Education, 6 January 2006
  10. ^ Jo Revill, "Doctor in drug research row quits NHS post", The Guardian, 15 January 2006
  11. ^ Zoe Corbyn, "Contractual ties trip up radiologist", Times Higher Education, 18 February 2010
  12. ^ "Professor Richard Eastell | Medical School | The University of Sheffield". www.sheffield.ac.uk. 3 February 2021. Retrieved 16 March 2021.
  13. ^ Endocrine Society
  14. ^ Jump up to: a b "Sheffield University pioneers osteoporosis research", News-Medical.net, 31 March 2004
  15. ^ "Frederic C. Bartter Award". American Society for Bone and Mineral Research. 22 January 2009. Retrieved 16 March 2021.

External links[]

Retrieved from ""